Adaptimmune Names New CMO, Reports Officer Departures
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $2,968, $1.34926 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
Related Tickers: ADAP
TL;DR
Adaptimmune's CMO is out, new one in. Standard exec shuffle.
AI Summary
Adaptimmune Therapeutics PLC announced on September 6, 2025, the departure of its Chief Medical Officer, Dr. Alasdair Davies. The company also reported the appointment of Dr. Joanna Horobin as the new Chief Medical Officer. Additionally, the filing includes information regarding compensatory arrangements for certain officers.
Why It Matters
Changes in key executive positions, particularly the Chief Medical Officer, can signal shifts in the company's strategic direction and clinical development pipeline.
Risk Assessment
Risk Level: medium — Executive changes, especially in critical roles like CMO, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- Dr. Alasdair Davies (person) — Departing Chief Medical Officer
- Dr. Joanna Horobin (person) — Appointed Chief Medical Officer
- September 6, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Joanna Horobin has been appointed as the new Chief Medical Officer.
Who is the departing Chief Medical Officer?
Dr. Alasdair Davies is the departing Chief Medical Officer.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 6, 2025.
What type of report is this filing?
This filing is a Current Report on Form 8-K.
What is the company's jurisdiction of incorporation?
The company is incorporated in England and Wales.
Filing Stats: 1,119 words · 4 min read · ~4 pages · Grade level 12.3 · Accepted 2025-09-08 16:05:16
Key Financial Figures
- $2,968 — s of 2,200 (equivalent to approximately $2,968) per day as compensation for provision
- $1.34926 — terling/U.S. dollar exchange rate of (1/$1.34926). Item 9.01 Financial Statements and E
Filing Documents
- adap-20250906x8k.htm (8-K) — 40KB
- adap-20250906xex10d1.htm (EX-10.1) — 138KB
- 0001558370-25-011925.txt ( ) — 314KB
- adap-20250906.xsd (EX-101.SCH) — 4KB
- adap-20250906_lab.xml (EX-101.LAB) — 16KB
- adap-20250906_pre.xml (EX-101.PRE) — 11KB
- adap-20250906x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1 Consulting Agreement dated as of September 6, 2025 by and between Adaptimmune Limited and CJH Financial Limited. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date: September 8, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary